web analytics

Glioblastoma; The Rise of Connectyx Technologies Holdings Group, Inc. (OTCMKTS: CTYX)

0

Connectyx Technologies Holdings Group, Inc. (OTCMKTS: CTYX) is making a powerful move up the charts after the Company entered into an Exclusive Evaluation and Commercialization Option License Agreement with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), for use of a novel monoclonal antibody in an antibody-drug conjugate to treat brain cancer. While the field of use covers treating adult and pediatric Glioblastomas, the Company is targeting pediatric Glioblastoma, an orphan disease, as the first indication for this product.

Cancer treatment is big news in small cap especially when the underlying Company has not debt on the books and just 322 million OS with 125 million of those shares restricted. Connectyx has been making big moves ever since SunMed Advisors, LLC acquired majority control of CTYX through the purchase of Series A Preferred stock with business whizz Paul M. Michaels taking over as CEO. Mr Michaels was instrumental in providing financial leadership for almost 18 years to Inabata & Co. Ltd., one of Japan’s largest trading companies with $4.5 billion in annual sales and successfully licensed multiple drugs from Gilead. Connectyx is currently working to become fully reporting OTCQB; to that end the Company appointed Jonathan D. Leinwand, PA as Legal Counsel.

Connectyx Technologies Holdings Group, Inc. (OTCMKTS: CTYX) is a development-stage biomedical company focusing on novel treatments for rare diseases. The Company also focuses on therapies with potentially accelerated development paths as a result of the indication, the nature of the therapeutic itself, or the stage of clinical development. The Company is transforming through the acquisition, in-licensing and sub-licensing of new technologies. At Connectyx, we envision a world where all patients have a therapeutic option. Connectyx aspires to grow into an organization that fulfills the unmet needs of patients with rare diseases through the development of pharmaceuticals and medical devices, either independently or through strategic partnerships.

MicroCapDaily first reported on CTYX in the first week of March of this year as the stock was beginning to move up off its triple zero lows. At that time Connextyx was undergoing a change of control as SunMed Advisors, LLC acquired majority control of CTYX through the purchase of Series A Preferred stock from the two principal holders of CTYX. Jon Pevzner resigned and Paul M. Michaels was appointed Interim CEO and Director. Dr. Barry A. Ginsberg and Brandon Michaels join Mr. Michaels on the Board. SunMed Advisors is a Life Science and Technology consulting firm that helps create maximum corporate value with strategic initiatives and a leading advisor on Pre-Commercial and Commercial-Stage licensing deals. SunMed brings value to all stages of licensing transactions, from sourcing through closing.

To Find out the inside Scoop on CTYX Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

CTYXThe new CEO is Paul M. Michaels; a busines whizz, responsible for opening up the Japanese market to US drug companies. He was instramental in internatianl transactions that influenced companies such as Celgene Corporation, Sumitomo Pharmaceuticals, Nobelpharma Co., Ltd, Teva Pharmaceuticals, ICOS, Neurocrine, Cell Therapeutics and Gilead, to name just a few. Paul has also provided financial leadership for almost 18 years to Inabata & Co. Ltd., one of Japan’s largest trading companies with $4.5 billion in annual sales and successfully licensed multiple drugs from Gilead (formerly Nexstar Pharmaceuticals). Paul M Michaels is a Harvard business graduate and founder of Sunmed Advisors and NobelPharma (a possible incoming business into CTYX).

Since taking over as CEO Paul M Michaels has been making a number of big moves including signing a definitive agreement with Mid-Atlantic BioTherapeutics, Inc. (MABT) to acquire worldwide rights for the development of IMT504, a novel, patented immunotherapy, to treat symptomatic rabies. IMT504 is being developed to treat patients whose disease has progressed beyond the stage where it can be treated by the existing approved rabies vaccines. IMT504 has been granted orphan drug designation in the US, which provides significant benefits including tax credits, market exclusivity and waiver of certain FDA fees. Rabies is one of only 14 diseases which qualify for the FDA Tropical Disease Priority Review Voucher (PRV) Program that is granted to sponsors of approved tropical disease product applications that meet certain criteria.

CTYX skyrocketed into multiple pennies after the Company reported it has entered into an Exclusive Evaluation and Commercialization Option License Agreement with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), for use of a novel monoclonal antibody in an antibody-drug conjugate to treat brain cancer.

The licensed patent rights include US Patent No. 10,548,987 issued February 02, 2020 (Patent Application No. 15/747,620 filed January 25, 2018). HHS Ref. No. E-221-2015-0-US-03. “ANTIBODY – DRUG CONJUGATES FOR TARGETING CD56 – POSITIVE TUMORS.” The territory is worldwide. While the field of use covers treating adult and pediatric Glioblastomas, the Company is targeting pediatric Glioblastoma, an orphan disease, as the first indication for this product.

Pediatric Glioblastoma – Roughly 28,000 children are living with a primary brain tumor in the U.S. with approximately 3,700 new diagnoses each year. Brain and CNS cancers are the most prevalent of all childhood cancers. The five-year survival rate depends on the size, location, and makeup of the cancer; for the most aggressive Glioblastoma, it is less than two years.

Paul Michaels, Chairman and President of CTYX said, “We are pleased to have added this cutting-edge technology to our development portfolio. Pediatric Glioblastoma is one of the deadliest childhood diseases with an average survival rate of less than two years. Recognizing the urgency for these patients and their families to find treatment options, our development plan anticipates being prepared for our First-in-Human clinical trial within 18 months, and our goal is to create a combined phase 1/phase 3 trial to accelerate development. We know these are extremely aggressive goals, but this is an extremely aggressive disease. At CTYX, we are building a pipeline of potential breakthrough medicines all of which can have an accelerated development pathway.”

For more on CTYXC Subscribe Right Now!

Currently on the move northbound CTYX is an exciting story developing in small caps; earlier this year Connextyx saw a change of control as SunMed Advisors, LLC acquired majority control of CTYX through the purchase of Series A Preferred stock from the two principal holders of CTYX. Jon Pevzner resigned and Paul M. Michaels was appointed Interim CEO and Director. Paul M. Michaels is a business whizz, responsible for opening up the Japanese market to US drug companies. He was instrumental in providing financial leadership for almost 18 years to Inabata & Co. Ltd., one of Japan’s largest trading companies with $4.5 billion in annual sales and successfully licensed multiple drugs from Gilead. CTYX just reported it entered into an Exclusive Evaluation and Commercialization Option License Agreement with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), for use of a novel monoclonal antibody in an antibody-drug conjugate to treat brain cancer. While the field of use covers treating adult and pediatric Glioblastomas, the Company is targeting pediatric Glioblastoma, an orphan disease, as the first indication for this product. Cancer treatment is big news in small cap especially when the underlying Company has not debt on the books and just 322 million OS with 125 million of those shares restricted. We will be updating on CTYX when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CTYX.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in CTYX either long or short and we have not been compensated for this article.

Share.

Leave A Reply

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.